4D Molecular Therapeutics (FDMT.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec17

4D Molecular Therapeutics Announces Positive Mid-Stage 1 Phase Results for 4D-710 in Treating Cystic Fibrosis Lung Disease

12:00

Nov12

4D Molecular Therapeutics Receives Buy Rating from H.C. Wainwright Analyst

11:19

Nov11

Morgan Stanley Reiterates Hold Rating on 4D Molecular Therapeutics

12:23

4D Molecular Therapeutics released FY2025 9 Months Earnings on November 10, 2025, EST: Actual Revenue USD 119 K, Actual EPS USD -2.8512

04:00

4D Molecular Therapeutics released FY2025 Q3 earnings on November 10 (EST), actual revenue USD 90 K (forecast USD 403 K), actual EPS USD -1.0133 (forecast USD -0.9916)

04:00

Nov6

4D Molecular Therapeutics Announces Positive Mid-Stage Results for 4D-150 Gene Therapy Drug

11:36

Schedules & Filings

Schedules

Filings

Nov10

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 90 K, Net Income -56.88 M, EPS -1.0133

Aug11

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 15 K, Net Income -54.66 M, EPS -0.9773

May8

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 14 K, Net Income -47.97 M, EPS -0.8605

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More